Citizens Jmp Issues Pessimistic Forecast for Savara (NASDAQ:SVRA) Stock Price

Savara (NASDAQ:SVRA) had its target price lowered by stock analysts at Citizens Jmp from $11.00 to $10.00 in a research report issued to clients and investors on Thursday,Benzinga reports. The firm currently has a “market outperform” rating on the stock. Citizens Jmp’s price target would indicate a potential upside of 132.56% from the stock’s previous close.

Other research analysts have also recently issued research reports about the company. Guggenheim increased their price objective on Savara from $8.00 to $11.00 and gave the stock a “buy” rating in a research report on Tuesday, September 9th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Savara in a research note on Wednesday, October 8th. HC Wainwright raised their price objective on shares of Savara from $5.00 to $8.00 and gave the company a “buy” rating in a research note on Wednesday, September 3rd. Oppenheimer boosted their price objective on shares of Savara from $6.00 to $8.00 and gave the stock an “outperform” rating in a report on Monday, September 8th. Finally, Wells Fargo & Company began coverage on shares of Savara in a report on Monday, October 20th. They issued an “overweight” rating and a $7.00 target price for the company. One analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, Savara presently has an average rating of “Moderate Buy” and a consensus price target of $8.29.

Savara Trading Up 0.9%

NASDAQ SVRA opened at $4.30 on Thursday. The company has a quick ratio of 11.08, a current ratio of 11.08 and a debt-to-equity ratio of 0.25. The stock has a market capitalization of $743.20 million, a P/E ratio of -8.60 and a beta of 0.45. Savara has a 52-week low of $1.89 and a 52-week high of $4.51. The firm has a 50-day moving average price of $3.81 and a 200 day moving average price of $3.06.

Savara (NASDAQ:SVRA) last released its earnings results on Wednesday, November 12th. The company reported ($0.14) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.13) by ($0.01). Equities research analysts expect that Savara will post -0.45 EPS for the current year.

Institutional Trading of Savara

Several large investors have recently modified their holdings of the business. Squarepoint Ops LLC acquired a new position in shares of Savara during the 3rd quarter worth approximately $90,000. F m Investments LLC increased its position in Savara by 37.8% during the third quarter. F m Investments LLC now owns 433,713 shares of the company’s stock worth $1,548,000 after buying an additional 118,867 shares in the last quarter. Rosalind Advisors Inc. increased its position in Savara by 50.7% during the third quarter. Rosalind Advisors Inc. now owns 4,000,000 shares of the company’s stock worth $14,280,000 after buying an additional 1,345,056 shares in the last quarter. UBS Group AG raised its holdings in shares of Savara by 221.2% in the third quarter. UBS Group AG now owns 695,734 shares of the company’s stock worth $2,484,000 after acquiring an additional 479,123 shares during the last quarter. Finally, BNP Paribas Financial Markets lifted its position in shares of Savara by 86.7% in the third quarter. BNP Paribas Financial Markets now owns 25,154 shares of the company’s stock valued at $90,000 after acquiring an additional 11,681 shares in the last quarter. 87.93% of the stock is currently owned by institutional investors and hedge funds.

About Savara

Savara Inc, formerly Mast Therapeutics, Inc, is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of novel therapies for the treatment of patients with rare respiratory diseases. Its pipeline includes AeroVanc, Molgradex and AIR001. AeroVanc is an inhaled formulation of vancomycin, which the Company is developing for the treatment of persistent methicillin-resistant Staphylococcus aureus, lung infection in cystic fibrosis patients.